echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Neuroblastoma in the UK is seeing the development of potential new therapies

    Neuroblastoma in the UK is seeing the development of potential new therapies

    • Last Update: 2021-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    UK's national research charity Neuroblastoma UK has received news that new treatments for children with neuroblastoma are entering clinical trials.
    the drug has passed adult safety trials and indirectly targets N-Myc, a gene that appears in an invasive form of neuroblastoma.
    the treatment, which blocks N-Myc activity by shutting down gene production, is expected to conduct a clinical trial in children with high-risk neuroblastoma by the end of 2020.

    In mice, the drug slowed down and stabilized tumor growth, and mice receiving the drug survived longer after treatment than untreated mice.
    when used in mice in combination with chemotherapy, these drugs shrink tumors to the extent that they can almost be eliminated.
    study of the therapy, fadraciclib, was led by scientists at the Institute of Cancer Research and published earlier this week in the Journal of Clinical Research.

    Tony Heddon, chairman of Neuroblastoma UK, said: "We welcome the news that new treatments are likely to be used in clinical trials and will reach more young cancer patients.
    less than 50 percent of children with high-risk neuroblastoma survive five years or more after diagnosis. For children who do survive, the drugs used to save them can cause long-term damage.

    “ There is a real need to provide our children with less toxic and more effective treatments. This important development offers real hope to families suffering from this life-threatening cancer. He added. (

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.